- Home
- SILC vs VERU Comparison
SILC vs VERU Comparison
Compare SILC & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- VERU
- Stock Information
- Founded
- SILC 1987
- VERU 1971
- Country
- SILC Israel
- VERU United States
- Employees
- SILC N/A
- VERU N/A
- Industry
- SILC Computer Manufacturing
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- SILC Technology
- VERU Health Care
- Exchange
- SILC Nasdaq
- VERU Nasdaq
- Market Cap
- SILC 86.2M
- VERU 85.5M
- IPO Year
- SILC 1994
- VERU 1990
- Fundamental
- Price
- SILC $18.51
- VERU $3.60
- Analyst Decision
- SILC Hold
- VERU Strong Buy
- Analyst Count
- SILC 1
- VERU 3
- Target Price
- SILC N/A
- VERU $33.33
- AVG Volume (30 Days)
- SILC 13.2K
- VERU 126.9K
- Earning Date
- SILC 10-30-2025
- VERU 08-12-2025
- Dividend Yield
- SILC N/A
- VERU N/A
- EPS Growth
- SILC N/A
- VERU N/A
- EPS
- SILC N/A
- VERU N/A
- Revenue
- SILC $58,651,000.00
- VERU $16,886,419.00
- Revenue This Year
- SILC $6.53
- VERU N/A
- Revenue Next Year
- SILC $14.10
- VERU N/A
- P/E Ratio
- SILC N/A
- VERU N/A
- Revenue Growth
- SILC N/A
- VERU 337.24
- 52 Week Low
- SILC $12.29
- VERU $2.64
- 52 Week High
- SILC $19.37
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- SILC 70.17
- VERU 52.43
- Support Level
- SILC $18.09
- VERU $3.24
- Resistance Level
- SILC $19.36
- VERU $3.94
- Average True Range (ATR)
- SILC 0.64
- VERU 0.19
- MACD
- SILC 0.22
- VERU -0.10
- Stochastic Oscillator
- SILC 75.85
- VERU 91.88
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.